Health 2.0 Europe 2011

27 - 28 October 2011, Berlin, Germany.
Following the success of the first edition in Paris in April 2010, the 2nd annual Health 2.0 Europe in Berlin has been announced. The 2010 event gathered over 500 delegates in its first year and showcased the best of Europe's Health 2.0 offerings with some American input too. Co-hosted with K.I.T. Group, the 2nd edition will reconvene all the leaders and stakeholders in web 2.0 health: IT solution providers, health professionals, patient organizations, health authorities, public and private insurance organizations, medical devices and pharmaceutical companies, telecom groups, VC and financiers, policy makers, academics and more...

2011 Program Highlights
Health 2.0 Europe integrates the best of European web/mobile based technologies, and compares, contrasts and contextualizes them with leading examples of Health 2.0 from around the world. Health 2.0 Europe will be seeing what works in the context of Europe's evolving healthcare systems, and what the "boundary-less" online world means for consumers and physicians working in distinct healthcare systems - all in the lauded format of "rapid-fire" technology demos, provocative keynotes, and interactive discussions. 2011 themes will include:

  • Patient and physician social networks
  • Search & content
  • Communities and data production
  • Consumer and provider tools
  • Health promotion and wellness 2.0
  • Behavior change tools
  • Privacy, data, trust
  • Data utility layer & tools
  • System integration
  • Health 2.0 financing
  • Mobile devices and smart phones

There'll also be a presentation of the latest thinking about Health 2.0 in the European context, special videos, and an unconference session.

A signature of the Health 2.0 conferences, Launch!, will be back by popular demand. Come witness live demos of debuting technologies that will shape the future of healthcare.

Make it your event. Get involved now!
To submit a topic, a speaker, or a start up for the Launch! session, or to inquire about becoming a partner of the event, please contact:

Pascal Lardier, Director, International conferences
This email address is being protected from spambots. You need JavaScript enabled to view it.

Historical Venue
After the Cité Internationale in April 2010, the 2011 event is taking us to yet another historical landmark: the Langenbeck-Virchow building of the Charité Hospital and University of Medicine.

It was built in 1914-15 to be the seat of the German Surgical Society and the Berlin Medical Association. From 1950 to 1976, the Parliament of East Germany was constituted in its auditorium and started convening in the Great Hall. After the collapse of Berlin Wall in 1989 and a long legal conflict, the German Surgical Society and the Berlin Medical Association returned to their home.

For further information and registration, please visit:
http://www.health2con.com/europe/

Most Popular Now

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Cells of 3 advanced cancers die with drug-like com…

Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggres...

Pfizer announces positive top-line results for pot…

Pfizer Inc. has announced that REFLECTIONS B3281006, a comparative safety and efficacy study of PF-05280586 versus MabThera® (rituximab-EU), met its primary endpoint. PF-...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]